With the help of Friends, families and Sponsors (Bloomberg, Davies Ward & Selerity) Vigilant Global’s Vigi4Cure team completed their fourth journey to Quebec City on July 11-12 with the Enbridge Ride to Conquer Cancer. A total of 1,347 participants raised a total of $4.9 million for the Segal Cancer Center at the Jewish General Hospital.
Not all conferences are created equal, and CleanMed is one of my very favorites. Some of the founding members of Practice Greenhealth and Healthcare without Harm, the conference organizers, were early adopters of environmentally responsible IT asset disposition (ITAD).
Funding will allow company to expand to additional markets
ATLANTA, April 29, 2015 /3BL Media/ – Cox Enterprises announced today an investment in Atlanta-based Rimidi, a digital health company focused on diabetes and other chronic conditions. This marks a major milestone for the company, paving the way for Rimidi’s expansion into additional markets and collaborative opportunities.
STEMAccelerator is helping kids prepare for exciting STEM careers and is supported through GSK's $1 million grant.
Multimedia with summary
The new Beyond GSK segment is centered on STEM (science, technology, engineering, and math) education and GSK’s one million dollar commitment to NC New Schools’ brand new initiative called STEMAccelerator. In this episode, you will meet Cyclops, a robot made from nuts, bolts, sensors and switches. Cyclops is one way that high school students in North Carolina are being inspired by science, technology, engineering, and math (STEM).
April 29, 2015 /3BL Media/ - GBCHealth and Global Health Council (GHC) are pleased to announce a call for applications for the 2015 GBCHealth-GHC Business Action on Health Awards. These awards highlight the important and innovative contributions of the corporate sector to improving global health outcomes.
The 50cc heart is the smaller version of the 70cc SynCardia Heart, which is FDA, Health Canada and CE mark approved. It is designed for implantation in most women, smaller men and many adolescents with end-stage biventricular heart failure.
March 31, 2015 /3BL Media/ - SynCardia Systems, Inc. has received FDA approval to conduct an Investigational Device Exemption (IDE) clinical study on the effective use of its 50cc SynCardia temporary Total Artificial Heart.